MorphoSys Expands Antibody Partnership With LEO Pharma - Quick Facts

(RTTNews) - LEO Pharma A/S and MorphoSys AG (MOR) announced an expansion of their existing strategic alliance to identify peptide-derived therapeutics for unmet medical needs. LEO Pharma will select targets against which MorphoSys will identify lead molecules using its peptide technology platform. LEO Pharma will either develop these lead molecules, or use them to aid the design of other drug candidates. LEO Pharma will have exclusive, worldwide rights and be responsible for development and commercialization of resulting drugs in dermatology. MorphoSys will have an exclusive option to secure worldwide rights to any drugs arising from the collaboration in the field of oncology.

MorphoSys will receive R&D funding as well as success-based development, regulatory and commercial milestone payments, plus royalties on net sales of peptide drugs commercialized by LEO Pharma.